GO:1901986 response to ketamine: Mechanisms and Genes

GO:1901986, response to ketamine, is a Gene Ontology biological_process term describing any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ketamine stimulus. Ketamine is a dissociative anesthetic that has attracted intense research interest because of its rapid antidepressant effects in treatment-resistant depression and related mood disorders. Understanding the molecular and cellular processes that constitute the response to ketamine is therefore central to both neuroscience and psychiatric drug development. The response to ketamine is not a single pathway but a coordinated set of cellular events, including glutamatergic signaling, changes in synaptic plasticity, altered gene expression, and downstream effects on neurotrophic and inflammatory mediators. Because these events are dynamic and context-dependent, researchers use a combination of genetic, electrophysiological, and biomarker approaches to dissect them. Genetic studies of response to ECT, TMS, ketamine, and esketamine highlight that inter-individual variability in treatment response has a heritable component, making candidate-gene and pathway-level investigation essential. Blood-based biomarkers, including BDNF and inflammatory markers, have been systematically reviewed as correlates of antidepressant response to ketamine and esketamine, providing accessible readouts of the response process. Electrophysiological biomarkers such as gamma power and long-term potentiation offer functional windows into the cortical and synaptic changes that accompany ketamine response. Non-pharmacological modulators, such as music, and frontal EEG features have also been explored as factors that may influence or predict clinical response to ketamine and esketamine. Comparative effectiveness data, such as the trial of esketamine nasal spray versus quetiapine for treatment-resistant depression, underscore the clinical importance of understanding and predicting response to ketamine-related treatments. This article integrates the QuickGO definition of GO:1901986 with verified PubMed literature to provide a research-grade overview of the mechanisms, genes, and experimental methods used to study response to ketamine.

In our own words, GO:1901986 (response to ketamine) refers to the collection of cellular and organismal processes triggered when a cell or organism encounters ketamine. It covers changes in movement, secretion, enzyme production, gene expression, and other activities that occur as a result of a ketamine stimulus. This term is intentionally broad: it encompasses immediate signaling events, such as glutamatergic modulation, as well as slower adaptive changes, including altered gene expression and synaptic remodeling. Because the definition is stimulus-centered rather than pathway-specific, it can be applied to diverse experimental systems, from cultured neurons to whole organisms, and to both clinical and preclinical ketamine exposure.

GO:1901986 is important because ketamine and its enantiomer esketamine are clinically used for treatment-resistant depression, and the biological processes that constitute the response to ketamine determine whether a patient improves. Dissecting this response helps researchers identify predictive biomarkers, understand mechanisms of rapid antidepressant action, and design safer or more effective treatment strategies.

The following genes and proteins have been implicated in the response to ketamine or in related antidepressant response pathways, based on the verified literature.

The response to ketamine is regulated at multiple levels, including glutamatergic signaling, neurotrophic pathways, and inflammatory mediators. Genetic variation in candidate genes contributes to inter-individual differences in response to ketamine and esketamine. Electrophysiological measures such as gamma power and long-term potentiation reflect regulated changes in cortical and synaptic activity during ketamine response. Non-pharmacological factors, including music, and frontal EEG features can further modulate or predict clinical response.

The response to ketamine is most directly linked to treatment-resistant depression, where ketamine and esketamine produce rapid antidepressant effects. Comparative effectiveness data, such as esketamine nasal spray versus quetiapine, highlight the clinical importance of understanding this response.

Blood-based biomarkers, including BDNF and inflammatory markers, have been systematically reviewed as correlates of antidepressant response to ketamine and esketamine in major depressive disorder. Electrophysiological biomarkers such as gamma power and long-term potentiation further link the response to ketamine to measurable disease-relevant biology.

Genetic studies of response to ECT, TMS, ketamine, and esketamine indicate that heritable factors influence treatment outcomes. This has implications for personalized psychiatry and for the design of studies that test candidate genes in the response to ketamine.

Non-pharmacological factors such as music and frontal EEG features have been studied for their impact on or prediction of clinical response to ketamine and esketamine. These findings suggest that the response to ketamine is influenced by a combination of biological and contextual factors.

Electrophysiological measures such as gamma power and long-term potentiation are used to track functional changes during ketamine response in treatment-resistant depression. Frontal EEG features have also been applied to predict clinical response to intranasal ketamine and esketamine.

Blood-based biomarkers, including BDNF and inflammatory markers, are measured to correlate with antidepressant response to ketamine and esketamine. Systematic review and meta-analysis provide frameworks for interpreting these biomarkers across studies.

Genetic studies of response to ECT, TMS, ketamine, and esketamine use candidate-gene and pathway approaches to identify variants associated with treatment response. These studies inform the selection of genes for functional validation.

Scoping reviews have examined the impact of music on response to ketamine and esketamine, illustrating methods for studying environmental modulators. Such studies complement biological and electrophysiological approaches.

Researchers studying response to ketamine-related genes often need to determine whether a candidate gene is causally involved in the cellular and organismal changes triggered by ketamine. EDITGENE provides the CRISPR tools and services required to move from genetic association to functional validation.

GO:1901986 (response to ketamine) provides a formal ontology framework for studying the diverse cellular and organismal changes triggered by ketamine. The verified literature links this process to rapid antidepressant effects, genetic variability, blood-based and electrophysiological biomarkers, and modifiable clinical factors. CRISPR-based models offer a powerful route to causal validation of candidate genes within this response, supporting both mechanistic discovery and translational research.